Official Title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder

Purpose

Brexpiprazole is a medication being studied as a possible treatment for adjunctive treatment for Major Depressive Disorder (MDD). The reason for this study is to find out about the potential benefits and safety of Brexpiprazole.

Could this study be right for you?

Inclusion criteria: - Between the ages of 18 and 65 - Currently depressed - Currently taking an antidepressant - Have tried at least 2 antidepressant medications

Age Range

18 and up

Official Title

A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy (SLEEP)

Purpose

The purpose of this study is to understand how Continuous Positive Airway Pressure (CPAP)
for mild to moderate sleep apnea may affect hypertensive disorders of pregnancy and other
complications of pregnancy such as gestational diabetes.

Could this study be right for you?

1. No prior delivery at or after 20 weeks 0 days of gestation
2. Pregnancy with only one fetus
3. Gestational age at randomization between 14 weeks 0 days and 21 weeks 6 days
4. Diagnosis with mild to moderate OSA as defined by an AHI score ≥ 5 and <30

Age Range

18 and up

Official Title

A5359; A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-adherent HIV-Infected Individuals

Purpose

This study is investigating if Long-Acting (LA) Injectable HIV-medications will be more successful for people who are non-adherent to their HIV medications than oral standard of care regimens. To be eligible to receive LA ART, participants will need to attain virologic suppression through adherence to an oral regimen first.

Could this study be right for you?

• Be between 18 - 75 years of age
• Previously prescribed ART for at least 6 months
• Screening HIV RNA is greater than 200 copies
• Women must not be pregnant, planning to become pregnant, or breastfeeding. Women who can become pregnant must agree to use 1 form of effective birth control
• Evidence of non-adherence to previous HIV medications

Age Range

18 and up

Official Title

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD (TERPSIS)

Purpose

To evaluate the efficacy and safety of study drug NBI-1065846, used as adjunctive treatment to oral antidepressant medication(s), compared with a placebo when treating symptoms of anhedonia.

Could this study be right for you?

• Aged 18-65 years old • Diagnosis of MDD • Currently on stable dose of at least one antidepressant • Experiencing anhedonia (low interest, decreased enjoyment)

Age Range

18 and up

Official Title

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19

Purpose

The purpose of this trial is to determine whether a commercially available dietary supplement may decrease the severity of patients with early COVID-19

Could this study be right for you?

Inclusion Criteria:

- Outpatients who test positive for infection with SARS-CoV-2
- Age 45 years and older
- Experiencing COVID 19 symptoms for 7 days or less,
OR 72 hours of new respiratory symptoms
- Patient must have access to the internet or a smartphone to complete surveys
- English-speaking patients

Age Range

45 and up

Official Title

Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Purpose

This is a 1-year open-label study to access the safety of REL-1017, a study medication, once daily as a workable treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.

This study will last 13 months and you will come to the study site at least 15 times over this period. This will include 1 final visit about 1 month after you stop taking the study drug.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking or having taken between 1 and 3 antidepressants for the current episode of depression

Age Range

18 and up

Official Title

M16-047: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids on Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Purpose

The purpose of this study is to compare the effectiveness and safety of Upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for adolescents (12-17 years of age) and adults (18-75 years of age with moderate to severe atopic dermatitis (AD).

Could this study be right for you?

- Adolescent subjects must weigh more than 40 kg (88 lb) - Subject must be in good general health (other than Atopic Dermatitis) - Subject must have chronic Atopic Dermatitis (AD) with onset of symptoms at least 3 years before first dose of study medication - Subject must have documented history of inadequate response to topical corticosteroids (TCS), topical calcineurin inhibitor (TCI), or systemic treatment for AD within 6 months prior to first dose of study medication - Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study and for 30 days after last dose of the study drug. - No history of drug or alcohol abuse in the 6 months prior to receiving the first dose of study medication

Age Range

12 and up

Official Title

Microdosed Atropine for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)

Purpose

The purpose of this study to test the safety and effectiveness of atropine 0.1% and atropine 0.01% eye solutions. These drugs are being tested to see if they slow the worsening of nearsightedness. Children who participate in this study will be asked to use their assigned study medication every night and willing to attend visits at The Ohio State University of Optometry 1 month after starting treatment. These visits will continue for 6 months until the duration of the study ends. This study will take place over a 4-year time period.

Could this study be right for you?

· Children aged 3 to < 13 years old. · No previous use of medications related to myopia control. · Glasses and/or contact lens prescription between -1.00 and -6.00 diopters. Interested guardians who believe their child may be eligible should contact study coordinators to further determine eligibility

Age Range

3 and up

Official Title

Art to promote Reduction in stress, Truncate severity of Gastrointestinal symptoms Understand its role in Therapy (ART-GUT study)

Purpose

The purpose of this study is to evaluate whether group-art sessions can reduce stress, improve sleep quality, improve quality of life and decrease severity of digestive symptoms in participants who suffer from chronic digestive issues. Participants will meet virtually once per week for 1.5 hour sessions, via Zoom, and will be provided with art supplies.

The start date will be determined by the date the 1st session starts for a given group. Thus participants can be in the study for up to 14 weeks.

Could this study be right for you?

• Male or females aged 18 years or older
• Suffer from Chronic Digestive Symptoms
• Willing to meet virtually once per week for 1.5 hour group sessions

Age Range

18 and up

Official Title

Breathing Reduces Enteric symptoms and Anxiety promoting Therapeutic Healing Experience (BREATHE) – A Randomized Clinical Trial in Patients with Symptoms of Gastroparesis

Purpose

The purpose of this research study is to see if practicing mindful breathing daily can reduce stress, improve sleep
and possibly improve symptoms in patients with Gastroparesis.

Gastroparesis is a condition characterized by symptoms such as nausea, vomiting, feeling excessively full after eating a little bit, bloating and abdominal pain. One or more of these symptoms can be present in a given patient.

Your participation throughout the study will last 6 weeks.

Could this study be right for you?

• At least 18 years of age
• Able to read and understand English
• Has symptoms of gastroparesis for at least 6 months (gastric emptying study is NOT required for inclusion)

Age Range

18 and up

Official Title

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Purpose

This study is being done to see if the study drug, called BI 1358894, compared to a drug called quetiapine, may help people with Major Depressive Disorder (MDD) who do not progress when taking an antidepressant medication alone. This study will help to gain information for providing better or new possible treatments for people in the future.

This study will take place over a period of 13 weeks and have about 8 visits to the study center and 2 that will be done by phone.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking an antidepressant

Age Range

18 and up

Official Title

The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism among African Americans: Pilot Study

Purpose

The purpose of this study is to find out if taking one medication Diovan (valsartan) or a combination of two medications (valsartan and sacubatril) in one pill called Entresto, will improve prediabetes in Blacks /African Americans over the course of 6 months. We will also look for changes in blood pressure and blood vessel stiffness throughout the course of the study in order to better understand how these medications may impact prediabetes.

Could this study be right for you?

Inclusion Criteria: - African American aged 18-65 years old - History of impaired fasting glucose - Impaired glucose tolerance - A1c 5.7-6.4% or other risk factors for diabetes Exclusion Criteria: - Type 2 diabetes - Systolic blood pressure greater than 150/100 or medications to lower your blood pressure - Systolic blood pressure less than 100/60 - Steroid use - Hyperkalemia (high potassium levels)

Age Range

18 and up